Introduction
The mouse has become an irreplaceable model system to study the molecular pathogenesis of cancer because it shares striking physiological, anatomical and genomic similarities with humans. The rapid development of novel methodologies for manipulating the mouse genome has allowed and will allow, in next few years, to recreate in the mouse virtually any pathological condition whose molecular basis has been elucidated in humans. Moreover, the large number of mouse mutants already generated (spontaneous, or created by chemicals or radiation), combined with the development of high resolution and physical linkage maps and the availability of a ®rst draft of the mouse genome sequence will allow the identi®cation of new genes associated with cancer susceptibility. Importantly, many of the molecular lesions that have been associated with a speci®c human cancer are causing a similar and often indistinguishable disease once introduced in the mouse genome and expressed in the appropriate cellular compartment. It is also evident, however, that modelling cancer in the mouse goes far beyond the simple mimicry of the human pathological condition, but rather provides invaluable insights into the mechanisms underlying the etiopathogenetic process.
While it has long been recognized that cancer arises because of the accumulation of genetic changes in somatic cells, eventually giving rise to overt malignancies, human lymphomas and leukaemias are often associated with recurrent chromosomal rearrangements more rarely observed in solid tumours (with the exception of certain forms of sarcomas). Frequently, these chromosomal rearrangements are epitomized by chromosomal translocations and/or inversions that often result in inappropriately high level of expression of cellular proto-oncogenes, or in the generation of fusion genes encoding chimeric oncoproteins. These chromosomal rearrangements speci®cally associate with particular leukaemia subtypes and result in the production of tumour speci®c mRNAs and proteins, which may represent attractive targets for therapy. In turn, the development of animal models for these malignancies can be used as valuable model systems for pre-clinical drug testing.
The focus of this review is to provide an overview of the current methodologies for modelling human leukaemia and lymphoma in the mouse. We will describe classic transgenic approaches as well as more recent knock-in, inducible and Cre-loxP based systems, providing speci®c examples that illustrate their utility and disadvantages. Finally, we will discuss examples of how mouse models of haematopoietic malignancies have been successfully used for developing new therapeutic approaches.
The transgenic approach
From an historical point of view, the ®rst successful manipulation of the mouse genome has been achieved by injecting with foreign DNA the pronucleus of the one cell-stage embryo immediately after fertilization. Once introduced into the pronucleus, the foreign DNA (i.e. the transgene), can be integrated in chromosomes at random sites (Figure 1) . Usually, the transgene retains regulatory elements that drive in vivo the expression of a gene of interest in a speci®c tissue/cell type of the adult organism and/or at an exact developmental stage during embryogenesis. This approach is still to date the most straightforward methodology available in order to test in vivo the oncogenic potential of any aberrant gene product. However, since the genetic alterations associated with leukaemia and lymphoma are often somatic lesions acquired in speci®c cells types, it is essential to restrict the expression of the transgene to the cellular compartment where the aberrant gene product should exert its eect. This speci®city can be achieved by constructing expression vectors in which appropriate promoters or regulatory elements direct the expression of the transgene in a speci®c target tissue/cell and/or in a speci®c phase of haematopoietic dierentiation.
Transgenic BCR-ABL mice in modelling ALL and CML
Although tissue speci®city of transgene expression proved in the last 10 years to be a key factor in modelling leukaemia and lymphoma in the mouse, the ®rst successful attempt of modelling leukaemia in mice was carried out using an ubiquitous promoter to test in vivo the oncogenic potential of the BCR-ABL fusion gene (Heisterkamp et al., 1990) . The BCR-ABL chimeric gene was cloned at the translocation breakpoint of the Philadelphia chromosome, the ®rst chromosomal abnormality to be found consistently associated with human cancer. Two isoforms of BCR-ABL, p210 and p190, are preferentially found in the blasts of patients with chronic myelogenous leukaemia (CML) and acute lymphoblastic leukaemia (ALL), due to distinct breakpoints in the bcr locus (Shtivelman et al., 1985; Mes-Masson et al., 1986; Griths et al., 1992) . The p210 fusion protein is a hallmark of CML, whereas approximately half of the ALL cases harbouring the Philadelphia chromosome express the p190 protein (Chan et al., 1987; Kurzrock et al., 1987; Hermans et al., 1987) . Mice transgenic for a metallothionein-1 gene promoter (MT)-BCR-ABL p190 DNA construct died of acute leukaemia (myeloid or lymphoid) 10 ± 58 days after birth, thus providing evidence for causal relationship between the Philadelphia chromosome and human leukaemia (Heisterkamp et al., 1990) . The MT promoter drives low, ubiquitous, but zinc-inducible transgene expression. By contrast, initial eorts to generate transgenic CML and ALL models induced by BCR-ABL p210 under the control of the bcr promoter failed because of deleterious eects of the construct during embryogenesis (Heisterkamp et al., 1991) . The MT promoter allowed, even in this case, to overcome embryonic lethality. MT-BCR-ABL p210 transgenic mice were Figure 1 The transgenic approach: constitutive, tissue-speci®c or inducible expression of a transgene. Transgenic animals carry an exogenous gene or fusion gene inserted randomly into their genome. Dierent classes of promoters can drive transgene expression: (a) constitutively active promoters, such as viral regulatory sequences; (b) promoters active only in speci®c tissues such as the haematopoietic compartment; (c) promoters induced only upon treatment with appropriate inducers, such as the zinc-dependent metallothionein-1 gene promoter. To generate transgenic mice, the DNA construct carrying the transgene is injected into one of the two pronuclei of a freshly fertilized egg, where it undergoes random integration into the genome. When the resulting zygote reaches the stage of a two-cell embryo, it is implanted in a pseudopregnant foster mother and the ospring is tested for the presence and appropriate expression of the transgene viable, and reproducibly developed acute B-lymphoblastic leukaemia (B-ALL) after treatment with zinc, becoming an invaluable model for pre-clinical studies (Honda et al., 1995; Voncken et al., 1995; see therapy chapter) . However, none of these transgenic lines developed CML or a myeloproliferative disorder. To date, the only model of BCR-ABL p210 -associated myeloproliferative disorder has been obtained in mice where the expression of the transgene is driven by the tec promoter. The tec gene encodes a cytoplasmic tyrosine-kinase preferentially expressed in the haematopoietic lineage. These mice exhibit marked granulocyte hyperplasia and develop a myeloproliferative disorder resembling human CML (Honda et al., 1998) . Furthermore, in some of these mice the myeloproferative disorder undergoes subsequent transformation in acute leukaemia, thus resembling the blastic phase of human CML. This makes the tec-BCR-ABL p210 transgenic model a unique tool to search for additional genetic events underlying the etiopathogenesis of the CML blastic crisis.
Acute promyelocytic leukaemia (APL) in mice: directing the expression of the fusion proteins to promyelocytes Another type of leukaemia that has been thoroughly studied in vivo in the mouse is acute promyelocytic leukaemia (APL), a distinct subtype of acute myeloid leukaemia characterized by a block in myeloid dierentiation at the promyelocytic stage. In APL, as a consequence of reciprocal and balanced chromosomal translocations, the retinoic acid receptor a gene (RARa) fuses with a variety of partners (X genes), leading to the generation of X-RARa + RARa-X fusion proteins. In the vast majority of cases the RARa gene is fused to the promyelocytic leukaemia gene (PML) located on chromosome 15q22 (de The et al., 1991; Goddard et al., 1991; Pandol® et al., 1991) . In a small subset of APL, RARa fuses to the promyelocytic leukaemia zinc ®nger gene (PLZF) on 11q23, the nucleophosmin gene (NPM) on 5q35, the nuclear mitotic apparatus gene (NuMA) on 11q13 or to the signal transducer and activator of transcription 5B gene (STAT5B) on 17q11 (Chen et al., 1993a,b; Redner et al., 1996; Wells et al., 1997; Arnould et al., 1999) . Initial eorts to model APL in the mouse failed because the strong and unrestricted expression of PML-RARa under the control of the b-actin gene or CMV promoters resulted in embryonic lethality and our unpublished observations) . As in the case of BCR-ABL, an inducible line of transgenic mice was generated in which the expression of PML-RARa was regulated by the MT gene promoter. Surprisingly, these mice did not develop leukaemia, but rather liver pathologies including the development of hepatocellular carcinoma after 5 days of zinc stimulation (David et al., 1997) . The rapid onset of liver neoplasias correlated with overexpression of the transgene, since the fusion protein was found to be expressed in altered tissues at much higher levels than in the surrounding normal liver tissues. In addition, overexpression of PML-RARa in hepatocytes resulted in a strong proliferative response (David et al., 1997) . All together these initial studies with ubiquitous promoters provided support for the oncogenic role of PML-RARa, but also emphasized the crucial need of targeting the expression of the transgene using tissue speci®c promoters, in order to overcome embryonic lethality, and to attempt to model APL in the mouse.
The search for appropriate myeloid speci®c promoters proved not to be an easy task. At ®rst, PMLRARa was expressed under the control of the CD11b promoter, a regulatory element that becomes activated relatively late during myeloid cells maturation. The transgenic mice were born, did not develop leukaemia, but presented instead a marked reduction of myeloid precursors and developed leuko-and neutropenia when exposed to sublethal irradiation (Early et al., 1996) . Similarly, restricted expression of PML-RARa to the CD34 + /haemopoietic stem cell/early myeloid compartment by means of c-Fes driven transcription was not leukaemogenic either (P Greer, personal communication).
While CD11b and Fes regulatory elements were probably driving expression of the PML-RARa transgene either too late or too early during myeloid cell maturation, the cathepsin G (hCG) promoter, which becomes active at the transition from myeloblasts to myelocytes, proved to be the best choice to restrict the in vivo expression of the transgene at promyelocytic stage of myeloid dierentiation, stage where the APL blasts are blocked. hCG-directed expression of PML-RARa caused a myeloproliferative syndrome characterized by a block in myeloid dierentiation at the promyelocytic stage in 100% of transgenic mice; 15 ± 30% of these mice went on to develop fatal APL-like leukaemia after a 6 to 14 month latency period (Grisolano et al., 1997; He et al., 1997) . These leukaemias recapitulated the features of human APL even in their exquisite response to all trans retinoic acid (AtRA) treatment, another distinctive feature of the human leukaemia. Another faithful mouse model of APL was generated using the human migration inhibitory factor-related protein 8 (hMRP8) promoter to drive the expression of PML-RARa (Brown et al., 1997) . The hMRP8 promoter becomes active at the myeoloblastic stage of myeloid dierentiation. hMRP8-PML-RARa transgenic animals also developed a myeloproliferative disorder that resulted in AtRA sensitive APL after a long latency.
Additional models of APL have been generated using the hCG minigene expression vector to drive the expression of two other fusion genes found in human APL: PLZF-RARa and NPM-RARa (He et al., 1998; Cheng et al., 1999) . These transgenic animals also developed myeloid leukaemias, after a long latency. Strikingly, hCG-PLZF-RARa transgenic mice developed AtRA-resistant leukaemias as observed in human APL harbouring this fusion protein. However, leukaemias in hCG-PLZF-RARa transgenic mice lacked the characteristic promyelocytic block in myeloid dierentiation and displayed features of human CML rather than APL, thus suggesting that PLZF-RARa is not sucient to trigger a full-blown APL phenotype and may need to cooperate with additional genetic event in this process.
Taken together, the analysis of the various X-RARa fusion products of APL in transgenic mice demonstrates their oncogenic properties in vivo. However, the long latency and the variable phenotypes that characterize these leukaemias suggest that X-RARa proteins are necessary and critical, but not sucient to cause APL.
As aforementioned, in human myeloid leukaemias chromosomal rearrangements often generate fusion genes, thus in turn reducing the dose of the normal parental alleles to heterozygosity. This becomes extremely relevant when the normal gene product acts as growth and tumour suppressive protein. By contrast, in the transgenic animal, the endogenous wild-type counterpart of the genes involved in the translocations is still present in normal dosage. This is indeed the case in human APL and in the various transgenic models of the disease. Furthermore, since the chromosomal translocations of APL and other haematopoietic malignancies are reciprocal and balanced, not only the various X and RARa genes are reduced to heterozygosity, but reciprocal RARa-X fusion genes are also generated.
The crucial importance of these aspects in APL cooperative leukemogenesis has been underscored by a combinatorial genetic approach utilizing transgenic and knock-out mice. The reduction of the dose of PML obtained by interbreeding PML-RARa transgenic mice with PML null mutants (PML-RARa/PML
) revealed a marked increase in the frequency of leukaemias and an earlier onset of the disease, compared to PML-RARa transgenic mice (Rego et al., 2001) . Even more notably, the reduction of the PLZF dose in PLZF-RARa/PLZF +/7 double mutants metamorphosed the CML phenotype observed in PLZF-RARa leukaemic mice into a leukaemia with classic APL features .
On the other end, the analysis of RARa-X transgenic mice and their crosses with X-RARa mutants has revealed the importance of the reciprocal product in APL pathogenesis. Remarkably, hCG-PMLRARa/RARa-PML double transgenic mice had a much higher incidence of leukaemia compared with PMLRARa littermate controls (Pollock et al., 1999) . However, the latency of leukaemia onset was the same in the two cohorts. Strikingly, RARa-PLZF also metamorphosed the CML phenotype observed in PLZF-RARa leukaemic mice into a leukaemia with classic APL features as observed in PLZF-RARa/ PLZF +/7 double transgenic mutants in agreement with the notion that RARa-PLZF can act as a dominant negative PLZF mutant .
Activation of proto-oncogenes in B-cell leukaemia and lymphoma
The classical transgenic approach has also proven very eective in modelling malignancies of the B-cell lineages, where chromosomal translocations represent a common mechanism of proto-oncogene activation.
In approximately 80% of neoplasms of B-cell origin, a cellular proto-oncogene becomes fused to the immunoglobulin (Ig) heavy-chain (IgH) locus on chromosome 14 or with one of the light-chain (IgL) loci on chromosomes 2 or 22. As a result of this fusion, powerful transcription enhancer elements exert their in¯uence on the juxtaposed proto-oncogene, leading to constitutively high levels of transcription. The ®rst prototypical example of such translocations was discovered in Burkitt lymphomas, where the c-myc gene was found juxtaposed to IgH or IgL sequences in nearly 100% of cases, leading to constitutive activation of the c-myc gene (Croce et al., 1984) . Transgenic mice carrying the c-myc oncogene coupled to enhancers, such as the immunoglobulin heavy-chain enhancer Em, were the ®rst attempts to model Burkitt lymphomas in vivo. Indeed, Em-c-myc transgenic mice developed fatal pre-B or B-cell lymphomas, but not Burkitt-like lymphomas, at high frequency after 6 weeks of age, thus demonstrating that c-myc expression is highly oncogenic in the B-cell compartment (Adams et al., 1985) .
The list of proto-oncogenes cloned at the breakpoints of B-cell lymphoma traslocations includes other key players in human tumorigenesis such as, for instance, bcl-2 and the cyclin D1 gene. Almost all human B-cell lymphomas with a follicular histology are associated with t(14;18) translocations involving bcl-2 and the IgH locus. Once again, transgenic mice expressing bcl-2 under the control of the Em enhancer develop lymphomas of the B-cell lineage (Strasser et al., 1993) . These lymphomas arose at a low incidence (3 ± 15%), and were associated with spontaneous translocations between the endogenous c-myc gene and immunoglobulin loci, indicating a genetic cooperation between these two genes during lymphomagenesis. Crossing bcl-2 and c-myc transgenic mice validated this hypothesis. Double transgenic mice exhibited accelerated lymphomagenesis in comparison with Em-c-myc transgenic mice, which likely resulted from the suppression of c-myc-associated apoptosis (Marin et al., 1995) . The Cyclin D1 gene was cloned at the frequent t(11;14) break-point of B-cell lymphomas and leukaemias. As in the case of bcl-2, Em-cyclin D1 transgenic mice developed lymphomas, and lymphomagenesis was accelerated by c-myc (Bodrug et al., 1994; Lovec et al., 1994) . Taken together all these experiments substantiated the idea that B-cell lymphoma is a multi-step process where deregulation of c-myc function plays a pivotal role. These models are now of great utility to identify such events as well as target gene using high throughput methodologies.
Transcription factors in T-cells leukaemias and lymphomas
Modelling human T-cell leukaemias and lymphomas in the mouse has been facilitated by the availability of several promoters to direct the expression of transgenes speci®cally to the T-lymphoid compartment. The CD2 locus control region (Zhumabekov et al., 1995) and the lck proximal and distal promoters, as examples, are regulatory elements shown to be sucient to drive Tcell speci®c transgene expression (Voncken et al., 1995; Wildin et al., 1995) , thus providing invaluable instruments for testing in vivo in the mouse the activity of aberrant gene products associated with T-cell acute lymphoblastic leukaemia (T-ALL) and/or T-cell lymphoma pathogenesis.
Several transcription factors involved in T-ALLassociated translocations are not normally expressed in lymphoid cells. It has been therefore hypothesized that ectopic expression of these factors contributes to leukaemogenesis. This hypothesis was veri®ed for the rbtn-2 gene, which is involved in t(11;14) translocation, by using CD2 regulatory sequences to direct its expression in the T cells compartment (Larson et al., 1994) : about 72% of the CD2-rbtn-2 mice developed T cell tumours of various stages of thymocyte maturation. Tumour development took approximately 10 months, indicating that additional mutations are required even in the presence of the transgene.
By contrast, CD2-mediated expression of the transcription factor tal-1, which is involved in the most common translocation associated with childhood T-ALL, t(1;14), did not cause lymphomas nor leukaemias in transgenic mice, suggesting that the transgene was perhaps expressed at the wrong stage of T-cell development (Curtis et al., 1997) . In fact, when tal-1 expression was directed to thymic immature T-cell progenitors, using the proximal promoter of the lck gene, these transgenic mutants did develop clonal T-cell lymphoblastic leukaemia (Condorelli et al., 1996) .
Once the oncogenic potential of a protein has been assessed in transgenic mice, the transgenic system becomes a powerful tool to determine in vivo the structural requirements for transformation. For example, by creating transgenic animals that express a mutant form of the tal-1 gene lacking the DNAbinding domain, once again under the control of the lck promoter, it was possible to demonstrate that the DNA-binding properties of tal-1 are not required for transformation in mice. Since both wild-type tal-1 and the DNA binding mutant formed stable complexes with E2A proteins, the authors suggested that the tal-1 protein contributes to leukaemia by interfering with E2A function (O'Neil et al., 2001) .
In conclusion, a conventional transgenic approach in the mouse still constitutes a very eective tool to study leukaemia and lymphoma in vivo. This methodology, although straightforward, has nevertheless several limitations, some of which are intrinsically related to the technical aspect of the procedure (e.g. the expression level of the transgene is heavily in¯uenced by copy number and the genome integration site). In addition, unrestricted or untimely expression of the transgene frequently results in embryonic-lethal phenotypes that can constitute a major impediment in assessing the oncogenic potential of the transgene. These technical hurdles can however be overcome by alternative approaches, which have been developed in the last few years, as we will discuss in the following paragraphs.
The`knock-in' approach
The knock-in approach has been recently utilized by a number of investigators to circumvent some of the disadvantages encountered by utilizing a conventional transgenic approach for the in vivo analysis of oncogenic events. This strategy takes advantage of homologous recombination in embryonic stem (ES) cells to introduce new genetic information into a genetic locus (Thomas and Capecchi, 1987) . In many cases, this strategy has been used to replace a gene with the oncogenic fusion product, which is consequently located under the control of its endogenous promoter, closely mimicking what is occurring, at a somatic level, in cancer cells (Figure 2 ). This replacement reduces the normal gene, if autosomal, to heterozygosity, as in the case of the majority of chromosomal translocations associated to leukaemia and lymphoma, and the relative dosage of the normal and aberrant gene is, in principle, comparable to the pathophysiological condition. Alternatively, a normal proto-oncogene can be knocked-in in a distinct locus to mimic the consequences of a chromosomal translocation (e.g. knockin of c-myc in the IgH locus). Another main advantage of the knock-in strategy is the elimination of the variegation eect due to the random insertion of the aberrant gene at dierent locations of the genome in transgenic mice.
The knock-in approach has been successfully utilized to target the BCR-ABL p190 fusion gene into bcr locus to generate mice which developed B-cell ALL, thus exactly reproducing the phenotype observed in human patients (Castellanos et al., 1997) . Similarly, the MLL-AF9 fusion gene has been introduced in the mouse by knock-in approaches to model acute myeloid leukaemia. The MLL gene (also known as ALL, or HRX) was cloned at the 11q23 breakpoint region, a genomic region associated with a remarkable spectrum of chromosomal abnormalities in over 20% of acute leukaemias. To date, at least 12 fusion partners involved in chromosomal translocations aecting MLL have been characterized (reviewed in Bernard and Berger, 1995 and Waring and Cleary, 1997) . Two of these partners, AF9 and ENL, code for proteins that are highly similar to each other and appear to act as bona ®de transcription factors (Rubnitz et al., 1994; Prasad et al., 1995) . Knock-in mice where the MLL-AF9 fusion gene was placed under the control of the Mll promoter developed acute leukaemias restricted to the myeloid compartment, in spite of the widespread activity of the Mll promoter (Corral et al., 1996) .
The knock-in approach has one fundamental limitation: while the gene rearrangements associated with human leukaemias occur at the somatic level, and, presumably, in haemopoietic progenitors, in the knocked-in animal the mutated gene is introduced in the germ cells as an inheritable character. Therefore, unlike somatic translocations resulting in the expression of an aberrant gene product in a speci®c subset of cells, the knocked-in gene is expressed throughout embryonic development to the same extent and in all the tissues where the normal gene is expressed. Many of the genes involved in cancer-associated translocations play an important role not only in haemopoiesis but also in development. In addition, fusion proteins identi®ed in human leukaemias often exert a dominant negative eect over their normal alleles. Therefore, one of the major disadvantages of the knock-in approach is the lack of tissue speci®city, which can result in embryonic lethality. This has been the case for the AML1-ETO fusion gene resulting from the t(8;21) translocation observed in the AML-M2 subtype of myeloid leukaemia. When the AML1-ETO fusion gene was knocked-in in the normal mouse Aml1 locus to model this leukaemia, the replacement resulted in embryonic lethality of the heterozygous mutant due to a block in foetal haemopoiesis, with a phenotype similar to the one observed in Aml1 7/7 mutants (Yergeau et al., 1997; Okuda et al., 1998) . Although the leukaemogenic role of AML1-ETO was not clari®ed in this experiment, the phenotype observed in the knock-in mutant was nevertheless extremely informative, since it supported the notion that the AML1-ETO fusion protein could act in vivo in a dominant negative manner to block AML1 function (Okuda et al., 1998) .
In conclusion, due to the aforesaid limitations, the knock-in approach will in many cases complement, but not replace, the transgenic approach. More recently, however, the knock-in approach has been coupled with the Cre-LoxP system in order to knock-in genes in a conditional (tissue or temporal speci®c) manner (see following paragraphs).
Tetracycline inducible systems
As previously discussed, embryonic lethality in both transgenic and knock-in approaches is a major limitation for the in vivo analysis of oncogenic gene products. A further complication in interpreting many of the resulting phenotypes could be caused by the systemic response of the animal to genetic changes carried throughout development. An ideal in vivo approach would therefore control the expression of the gene of interest in a tissue speci®c and in a tightly inducible manner. Early attempts made use of promoters that could be induced by heavy metals. Examples of eective utilization of this strategy in assessing the oncogenic potential of BCR-ABL and PML-RARa have already been discussed. However, this system had two main limitations: these promoters drive ubiquitous expression of the transgene and, in spite of their inducibility by heavy metals, they exhibit high basal activity (leakiness). To overcome these limitations binary in vivo systems have been developed in which gene expression is controlled by the interaction of two components: aǹ eector' and a`target' transgene. In the most classical of these binary systems, the eector protein transactivates transcription of the target transgene (for a recent review, see Lewandoski, 2001 ). Figure 2 The knock-in approach. The knock-in approach results in the replacement of the endogenous gene with its oncogenic counterpart at the physiological genetic locus. To this aim, a targeting vector is constructed containing two regions of homology to the desired chromosomal integration site¯anking the fusion gene of interest and a selectable marker, commonly the neo (neomycin phosphotransferase) resistance gene cassette. The targeting vector is transfected into embryonic stem (ES) cells, where homologous recombination between sequences of the vector and the genomic locus will result in the replacement of the target gene with the fusion gene and the selectable marker (targeted locus). Clones of ES cells resistant to drug selection are analysed to identify those that harbour a proper recombined locus. Recombined clones are then independently microinjected into a blastocyst, which is transferred to a pseudopregnant female. The resulting progeny is screened for pups that have germline transmission of the recombined locus, in order to select heterozygous targeted mice ®rst, which are next crossed to produce mice carrying the homozygous mutation
The most widely used inducible approach is the tetracycline-dependent regulatory system developed by Gossen and Bujard (1992) . In this system, the eector, or tetracycline transactivator (tTA), is a fusion protein where the VP-16 transactivation domain is fused to the Escherichia coli tetracycline repressor protein (TetR). tTA speci®cally binds both tetracycline and the operator sequences (tetO) of the tet operon, cloned upstream of the target transgene. In the original and mostly used version of this system, the tTA cannot bind DNA when the inducer (tetracycline) is present (`tet-o', see Figure 3 ), whereas in a modi®ed version, the`reverse tTA' (rtTA) binds DNA only when the inducer is present (`tet-on').
The tet-o inducible system has recently been applied to overcome the embryonic lethal phenotype caused by AML1-ETO and to investigate its role leukaemogenesis. AML1-ETO tet-o mice were generated by crossing transgenic mice containing the AML1-ETO cDNA driven by the tetracycline operator sequences with transgenic mice in which tTA expression was controlled by the mouse mammary tumour virus (MMTV) promoter (MMTV-tTA transgenic mice). Upon removal of tetracycline from the drinking water, high levels of AML1-ETO protein were observed in the bone marrow and in the peritoneal macrophages of these mice, accompanied by a partial block in myeloid dierentiation. Surprisingly, however, these mice failed to develop leukaemia (Rhoades et al., 2000) . This can be due to the fact that AML1-ETO is not sucient for leukaemogenesis. Alternatively, it is possible that once driven by the MMTV promoter, although regulated in time, the expression of the AML1-ETO transgene may not be directed to the exact haematopoietic cell compartment or maturation stage where AML1-ETO exerts its full leukaemogenic potential.
More recently, the tetracyclin-dependent regulatory system has been further re®ned to confer cell type/ tissue speci®city. Such approach has been employed to conditionally express a c-myc transgene in haemopoietic cells. To confer tissue speci®city, transgenic mice expressing c-myc under the control of the tetracycline operator were crossed with transgenic animals where tTA expression was driven by the immunoglobulin heavy chain enhancer and the SRa promoter (Em-tTA; Felsher and Bishop, 1999) . Transgenic mice developed malignant T-cell lymphomas as well as acute myeloid leukaemias, upon removal of tetracycline. Inactivation of the transgene by addition of tetracycline prevented the further development of tumours, and caused regression of the tumours already established (Felsher and Bishop, 1999) . The dierent pattern of leukaemic phenotype observed in these mice compared to the Emmyc transgenic animals which developed B-cell leukae- Figure 3 Inducible expression of a transgene by a tetracycline-based transactivation system. Inducible transgene expression by tetracycline-regulated systems has been applied to animal modelling to circumvent the problem of embryonic lethality or complex phenotypes generated by the indiscriminate expression of certain transgenes. The most widely used version of the tetracyclineinducible system is the`tet-o' system. In this system, the transgene is cloned under the control of the operator sequence (tetO) of the Escherichia coli tet operon. In the transgenic mouse carrying this construct, the transgene is not expressed. Another transgenic animal is then generated, expressing the tetO-transactivator protein (tTA) under the control of either a constitutive or a tissue speci®c promoter. The tTA transactivator is able to bind both tetracycline and the tetO sequence in the transgene construct. In the tet-o system, the tTA protein is prevented from binding the tetO sequence and transactivating the transgene when complexed to tetracycline. In the double transgenic animals, expression of the transgene is therefore regulated by removal of tetracycline Oncogene Mouse models of haematopoietic malignancies R Bernardi et al mias (Adams et al., 1985) , could be attributed to the dierent strains used by the investigators or to dierent minimal promoters in their constructs. Nonetheless, applying the inducible tet-o system to myc-mediated tumorigenesis allowed the authors to conclusively demonstrate that continuous myc expression is necessary to sustain tumour development. Reversibility of tumorigenesis was also demonstrated in the case of acute B-cell leukaemias induced by BCR-ABL. Mice harbouring a BCR-ABL transgene inducible by removal of tetracycline developed fatal B-lymphoid leukaemias that completely regressed upon tetracycline re-administration, in turn demonstrating that BCR-ABL-induced B-ALL is absolutely dependent on continued expression of the oncogene even at advanced stages of leukaemia (Huettner et al., 2000) . Taken together, these important results prove that, despite the multistep nature of tumorigenesis, rescue of a single genetic lesion can reverse tumorigenesis and can be therefore considered of therapeutic importance.
The Cre-loxP system
The use of site-speci®c DNA recombinases has further expanded the array of genetic manipulations that can be carried out in mice in order to study the pathogenesis of haemopoietic malignancies. Although various site-speci®c DNA recombinases, such as the yeast-derived Flp/frt (Farley et al., 2000) , are becoming increasingly popular, the Cre-loxP system is currently the most widely used in manipulating the mouse genome (Sauer and Henderson, 1988) . Cre is a sitespeci®c DNA recombinase derived from the P1 bacteriophage that recognizes 34 base pair sequences termed loxP sites. Cre catalyzes the deletion of a segment of DNA that is¯anked by loxP sites (¯oxed), leaving a single loxP site (Figure 4a ), or the inversion of the¯oxed DNA segment if the¯anking loxP sites are placed in opposite orientation. The Cre-loxP system represents an ideal instrument to manipulate chromosomal organization in vivo. In fact, loxP sites can be introduced by homologous recombination in any given region of the mouse genome. In parallel, mutants expressing the Cre recombinase in any given tissue or cell type speci®c manner are generated. By creating databases of transgenic mice expressing Cre in speci®c tissues and/or at speci®c times in development, this system can be used for virtually any application of gene targeting. The Cre-loxP system was initially developed for the generation of conditional knock-out mutants lacking the gene of interest only in a speci®c tissue or cell-type. In this system, the loxP sites are usually located in intronic regions,¯anking the coding region of the gene to be inactivated. The knock-out mouse is generated crossing these mutants with a transgenic mouse which expresses the Cre recombinase in a tissue/cell type speci®c manner. More recently, this system has also been applied to engineer subtle alterations in genes and/or their regulatory sequences, to regulate in a very selective way transgene activation anked by two loxP sites, are placed between the promoter and the gene, thus preventing transcription of the downstream cDNA. This mouse is next crossed with a second transgenic animal in which the Cre gene is expressed in a tissue speci®c manner. In the double transgenics, Cre will excise the intervening sequence located between the loxP sites, thus moving the promoter near the coding region of the fusion gene and resulting in activation of its expression only in the tissue or cells in which the Cre gene is expressed. (c) Strategy for Cre-induced chromosomal translocation. The genomic loci to be recombined are sequentially targeted by homologous recombination with loxP sites in appropriate intronic sequences. The targeted genes are thus fully functional, and the resulting double transgenic mutants are intercrossed with transgenic animals in which the Cre gene is expressed in the haemopoietic compartment. Expression of Cre will recombine the loxP sites (now located in trans), thus translocating the two genes in a reciprocal manner, only in the tissue or cells where the Cre gene is expressed (by removal of inhibitory sequences) or inactivation, as well as to induce large-scale chromosomal rearrangements such as chromosomal translocations. Due to the consequence of the genomic alterations associated with human haematopoetic malignancies (i.e. over-expression of proto-oncogenes and creation of aberrant fusion genes), the usefulness of the Cre-loxP system in the in vivo study of leukaemia and lymphoma will be mostly appreciated in two of its multiple applications: (i) conditional transgene expression and (ii) conditional generation of chromosomal translocations.
In vivo Cre-loxP mediated haemopoietic-specific transgene expression
Although originally developed for conditional gene targeting, the Cre-loxP system has been successfully modi®ed in order to obtain tissue speci®c activation of any aberrant gene associated with a speci®c disorder. The experimental approach consists of three distinct phases: (i) generate a transgenic animal where the gene of interest is silent because intervening sequences, anked by two loxP sites, are placed between a strong promoter and the gene thus preventing transcription of the downstream cDNA; (ii) generate transgenic animals in which the Cre gene is expressed in a tissue speci®c manner, and more speci®cally, in the haemopoietic compartment; and (iii) intercross these transgenic lines. Animals generated from this breeding will be transgenic for both constructs. As a result, Cre will excise the intervening sequence separated by the loxP sites, moving the strong promoter close to the coding region of the fusion gene and resulting in transactivation of the gene only in the tissue or cells in which the Cre gene is expressed (Figure 4b) .
The main advantage of this three-step approach is that it combines high levels of expression driven by a strong promoter with the speci®city granted by the tissuespeci®c expression of the Cre protein. This aspect is of particular relevance when the pathological condition may depend on high level of gene/transgene expression.
Alternatively, the Cre-loxP system can be coupled with the knock in approach. In this case the fusion/ aberrant protein is knocked in an intron of the target parental gene (e.g. PML-RARa in a PML intron) and is preceded by a loxP site. A second loxP site is introduced at or just before the ATG of the wild-type protein. Upon Cre-mediated recombination in a tissue/ time speci®c manner the fusion protein is knocked in the wild-type locus thus replacing it and lending under the control of the endogenous promoter.
In vivo Cre-loxP mediated haemopoietic-specific chromosomal translocation
Possibly one of the most sophisticated resorts in modelling leukaemia in the mouse takes advantage of the properties of the Cre recombinase. As already discussed, the products of chromosomal translocations are frequently involved in the genesis of haemopoietic malignancies leading to the formation of pathogenic fusion genes, and faithful mouse models for these disorders have been generated in many cases employing transgenic and knock-in approaches. However, these approaches often fail to recapitulate the genetic complexity observed in these malignancies. This is particularly true in the case of leukaemias carrying balanced translocations, where two reciprocal fusion genes concurring to leukaemogenesis are generated . Thus, in a perfect mouse model, de novo creation of somatic and tissue speci®c chromosomal translocations would be desirable. The Cre-loxP system allows mimicking these translocations in mice by favouring recombination between loxP sites introduced by homologous recombination in genomic loci located on distinct chromosomes (Smith et al., 1995) . This experimental procedure consists again of three distinct phases: (i) generate by homologous recombination a transgenic animal in which loxP sites are introduced in the two genes to be translocated, in locations corresponding to the breakpoints of the human translocation. The targeted genes are thus fully functional, and the resulting transgenic mice are viable; (ii) generate transgenic animals in which the Cre gene is speci®cally expressed in the appropriate haemopoietic compartment; and (iii) intercross these two transgenic lines. As a result, Cre will recombine the loxP sites, thus translocating the two genes in a reciprocal manner, only in the tissue or cells where the Cre gene is expressed (Figure 4c ). Successful attempts have been carried out to induce inter-chromosomal recombination of Mll and Af9 or Aml1 and Eto genes (Buchholz et al., 2000; Collins et al., 2000) . In both cases, the involved loci were successfully translocated not only ex vivo in primary cell lines, but also in vivo, thus demonstrating the feasibility of inducing recombination between non-homologous chromosomes in mice. This approach will allow to unravel the oncogenic potential of distinct chromosomal translocations associated with human cancer and, combined with transgenic and knock-in strategies, will shed new light into our understanding of the combined role of fusion products in the pathogenesis of haemopoietic malignancies.
In summary, the recent development of sophisticated genetic techniques for manipulating the mouse genome has allowed extraordinary advances in the generation of accurate models for human haemopoietic malignancies as well as in our understanding of the mechanisms underlying such pathologies. Although, in many cases, initial attempts of reproducing the human condition in mice were unsuccessful, these studies did nevertheless add insights to our understanding of their molecular pathogenesis. It is only by integrating the information obtained through the use of distinct in vivo methodologies that a more comprehensive knowledge on these processes will eventually be obtained.
Mouse models of haemopoietic malignancies for the development of novel therapeutic modalities
Anatomically faithful and molecularly de®ned animal models of human cancer are straightforward tools for the optimization of preexisting therapeutic modalities and the testing of novel ones. In the case of haemopoietic malignancies, the presence of speci®c molecular lesions (e.g. chimeric proteins that associate to speci®c forms of leukaemias) allows for the identi®cation and testing of drugs with very high speci®city for these molecular signatures. The mouse has already proved a very useful tool to test new compounds for the treatment of haemopoietic malignancies in transplantation model systems where human primary blasts or leukaemia/lymphoma cell lines are engrafted in mice with severe combined immunode®-ciency (SCID). The main disadvantage of this approach is that it suers from the heterogeneity and complexity of human cancer when primary blasts are utilized, and from the additional profound aneuploidy observed in many cancer cell lines. Thus, engineered mouse models allow testing therapeutic modalities in preclinical studies performed in a de®ned and more homogeneous genetic background. Indeed, transgenic models of APL and ALL-CML have recently proven extremely useful to test novel therapeutic modalities, as we will discuss in the next paragraphs.
APL
Dierentiation-inducing therapy by all-trans retinoic acid (AtRA) is now a standard therapy in patients with acute promyelocitic leukaemia (Warrell et al., 1991 Grignani et al., 1994; Pandol®, 1996) . AtRA induces complete remission in 70 ± 90% of APL patients harbouring a PML-RARa translocation (Fenaux and Degos, 1997; Tallman et al., 1997) . By contrast, APL harbouring a PLZF-RARa translocation do not respond or respond poorly to AtRA treatment (Licht et al., 1995) . The induction of remission by AtRA is associated with the terminal dierentiation of immature leukaemic blasts into neutrophils, followed by the restoration of normal haematopoietic stem cells in the bone marrow of APL patients . However, many APL patients relapse following AtRA treatment, and acquire secondary resistance . Mutations in the ligand-binding domain of the PML-RARa fusion protein are found in relapsed APL patients (Ding et al., 1998; Imaizumi et al., 1998) and in AtRA-resistant APL cell lines (Shao et al., 1997; Nason-Burchenal et al., 1998) , in turn implicating PML-RARa in mediating AtRAinduced dierentiation (Benedetti et al., 1996) .
As previously mentioned, X-RARa transgenic mice have been used to test leukaemia response to AtRA, and the results are consistent with what observed in human APL: leukaemic PML-RARa mice attained transient complete remission upon AtRA treatment, while PLZF-RARa mice never achieved remission although the treatment slightly prolonged their survival (Brown et al., 1997; Grisolano et al., 1997; He et al., 1997 He et al., , 1998 . At relapse, leukaemia in PML-RARa mice was found to be AtRA insensitive, as often the case in human APL (He et al., 1998) . These experiments proved that X-RARa transgenic mice represent an invaluable model system to study the mechanisms of constitutive and acquired AtRA resistance, as well as to develop and test new therapeutical approaches in order to overcome resistance to AtRA or to potentiate its therapeutic eects.
Combinations of complementary or synergistic antitumoural drugs are often utilized in cancer therapy. Mouse models of APL have been instrumental in demonstrating the synergy between AtRA and two novel compounds: arsenic trioxide (As 2 O 3 ) and histone deacetylase inhibitors (HDACIs) such as suberoylanilide hydroxamic acid (SAHA). As 2 O 3 , a chemical used in traditional Chinese medicine, has recently been shown to be eective in multi-relapsed APL patients. Ninety per cent of the APL patients treated in two independent studies underwent complete remission after treatment with As 2 O 3 alone, or, in a few cases, in combination with AtRA (Shen et al., 1997; Soignet et al., 1998) . In vitro studies in APL cells showed that As 2 O 3 could act as a growth inhibitory and proapoptotic agent by downregulating BCL-2 or upregulating the expression of caspases Shao et al., 1997; Soignet et al., 1998; Wang et al., 1998) . As 2 O 3 was also shown to induce the degradation of the fusion protein PML-RARa possibly through ubiquitination of the PML moiety Kamitani et al., 1998; Soignet et al., 1998; Wang et al., 1998) . Since AtRA and As 2 O 3 have been shown to act on dierent pathways ± AtRA by triggering dierentiation of myeloid blasts and As 2 O 3 by inducing apoptosis ± they would be expected to synergize in treating APL blasts. By contrast, since PML-RARa is thought to be important in mediating AtRA response, the fact that As 2 O 3 induce the degradation of this fusion protein may suggest that the two compounds antagonize each other. To study the eects of combining these two drugs in vivo, PML-RARa leukaemic mice and syngenic grafts of leukaemia blasts from PML-RARa transgenic mice have been used as model systems. In this context it has been shown that arsenic alone induced apoptosis and modest dierentiation of leukaemic cells, prolonged mice survival and induced complete leukaemia remission. Furthermore, the combination of arsenic with AtRA accelerated tumor repression through enhanced dierentiation and apoptosis. Although AtRA or arsenic alone only prolonged survival 2 ± 3-fold, association of the two drugs resulted in tumour clearance after a 9 month relapse-free period (Lallemand-Breitenbach et al., 1999; Rego et al., 2000) . On the other hand, neither in PLZF-RARa transgenic mice nor in nude mice transplanted with PLZF-RARa cells did any regimen of treatment (AtRA, As 2 O 3 or AtRA+As 2 O 3 ) induce complete disease remission . In the same study, the authors also demonstrated that therapeutic doses of AtRA and AtRA+As 2 O 3 can induce both in vitro and in vivo, the degradation of PML-RARa as well as PLZF-RARa, suggesting that the maintenance of the leukaemic phenotype depends on the continuous presence of the former, but not the latter (Rego et al., 2000) .
Some of the key molecular events in APL pathogenesis, which could explain the dierential response to AtRA on the basis of the transcriptional silencing properties of the X-RARa fusion proteins, have been recently identi®ed. In the absence of ligand (AtRA), both natural RARa and X-RARa fusion proteins repress transcription by recruiting histone deacetylases (HDACs) through direct interaction with nuclear corepressors such as NCoR/SMRT, that in turn directly contact HDACs (Grignani et al., 1998; Guidez et al., 1998; He et al., 1998; Lin et al., 1998; Minucci and Pelicci, 1999; Xu et al., 1999; Glass and Rosenfeld, 2000) . AtRA induces a conformational change in RARa that leads to dissociation of HDAC complex and recruitment of coactivators, thus leading to activation of transcription (Glass and Rosenfeld, 2000) . X-RARa proteins bind the ligand with the same anity of the wild-type receptor, but do not dissociate from NCoR/ SMRT at physiological concentrations of AtRA. Pharmacological doses of AtRA can induce the dissociation of the PML-RARa corepressor complex, while PLZF-RARa through the PLZF moiety can make corepressor/HDAC interactions that are AtRA insensitive (Grignani et al., 1998; He et al., 1998; Lin et al., 1998) . The logical implication of these ®ndings is that HDACIs should potentiate AtRA eects in responsive APL patients and may overcome AtRA resistance in patients harbouring PLZF-RARa.
Mouse models of APL have been utilized to test this hypothesis. Using PML-RARa and PLZF-RARa transgenic mice, it has been shown that HDACIs, such as trichostatin A (TSA) or suberoylanilide hydroxamic acid (SAHA), in combination with AtRA, can overcome the transcriptional repressor activity of PMLRARa and PLZF-RARa, and can overcome AtRA resistance of leukaemic cells from PLZF-RARa transgenic mice (He et al., 1998 . Inhibition of proliferation and induction of apoptosis observed in the presence of HDACIs are potentiated by AtRA, and, conversely, AtRA-induced dierentiation is enhanced by HDACIs, though no dierentiation could be induced by HDACIs alone (He et al., 1998 . Despite their marked antitumoural activity, these compounds display negligible toxicity in mice at doses that were able to induce accumulation of acetylated histones in peripheral blood and bone marrow cells. Moreover, long-lasting leukaemia remission was induced in mouse models of therapy resistant APL such as PLZF-RARa/RARa-PLZF double transgenic mice .
Recruitment of HDACs may also be essential for the transforming activity of AML1-ETO or the BCL-6 proto-oncogene of Non-Hodgkin lymphoma, suggesting that HDACIs may also be utilized in the treatment of haemopoietic malignancies other than APL.
On the basis of these ®ndings and the promising results obtained in preclinical studies in mouse leukaemia models, formal clinical trials with combinations of AtRA and As 2 O 3 in APL, as well as phase I trials with HDACIs, are currently ongoing in many clinical centers.
ALL and CML
Mouse models of BCR-ABL-associated haemopoietic malignancies have also proven extremely useful in testing novel compounds and therapeutic modalities. As aforementioned, the chromosome Philadelphia and the BCR-ABL fusion protein are hallmarks of CML, but are also found in a subgroup of patients with acute lymphoblastic leukaemia (ALL) characterized by a poor prognosis. BCR-ABL acts as a constitutively active version of the ABL kinase (Konopka et al., 1985) . This aberrant tyrosine kinase activity is essential for its transforming ability (Lugo et al., 1990) . Consequently the use of tyrosine kinase inhibitors seems a straightforward and rationale therapeutic modality. 2-phenylaminopyrimidines, a series of compounds based on the known structure of the protein kinase ATP-binding site, were the ®rst compounds to be reported to inhibit protein tyrosine kinases with selectivity for ABL and PDGF-R (Buchdunger et al., 1995 . STI517, the most potent of these compounds, was found to inhibit ABL, PDGFR as well as the Kit receptor in vitro (Buchdunger et al., 1995 and to reduce the proliferation of cells from CML patients Deininger et al., 1997) . Studies in nude mice demonstrated that CML-like tumours could be eradicated by continuous administration of STI517 (le Coutre et al., 1999) . STI517 or Glivec is currently approved for the treatment of CML. Farnesyl transferase inhibitors, such as SCH66336, are a second category of compounds that is currently being tested in murine models of BCR-ABL-positive acute lymphoblastic leukaemia. The Ras pathway is activated by BCR-ABL and these inhibitors are able to contrast the activation of Ras, which is dependent on its farnesylation. Administration of SCH66336 to early leukaemic MT-BCR-ABL transgenic mice caused suppression of the leukaemic phenotype and allowed disease-free survival in 80% of treated mice for the duration of the study (Reichert et al., 2001) . These results suggest that inhibition of farnesyl transferase may be of therapeutic bene®t in BCR-ABL-positive B-ALL, a disease where STI517 is only of temporary bene®t (Druker et al., 2001 ).
Conclusions
Our ability to manipulate gene expression in vivo in the mouse has increased exponentially in the last few years. Mouse mutants have already become invaluable tools for the study of normal and aberrant haematopoiesis. These novel methodologies will be important for the generation of faithful mouse models of human haemopoietic malignancies, but will also enable the identi®cation of novel diagnostic and prognostic indicators through high throughput analysis as well as the development of novel therapeutic modalities. However, the exploitation of these powerful genetic tools is still in a very primordial phase. The development of more subtle ways of controlling gene expression in vivo along with the re®nement of the approaches currently available will allow the production of mouse models that more precisely recapitulate the human disease and provide a greater understanding of the etiopathogenetic process. Furthermore, the increasing number of mutants that have already been and will be generated and characterized in the future will help in facing the tremendous challenge of complexity posed by the multistep nature of the neoplastic process and by the molecular intricacy arising from the post-genome aftermaths.
